Vivos Therapeutics, Inc. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Vivos issued 12,000 shares of Series C Convertible Preferred Stock (stated value $12 million, conversion price $0.15/share) to SOD Sciences in exchange for: (1) an 11% fully diluted equity interest in SOD (2,907,338 SOD common shares based on 23.5M pre-closing fully diluted shares), and (2) a 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test IP. Vivos and SOD will split contribution margin 50/50 on test sales; Vivos retains 80% margin on its own product sales through SOD's channels (American Health Associates and Cleveland Clinic Weston). No cash paid. Closing expected October 15, 2026, subject to auditor concurrence, Series B holder consent, and Nasdaq notification.
Why this rating
Deal equals 52% of Vivos's $22.9M market cap; $12M equity value material in size. Adds IP co-ownership and minority stake in operating partner with established channel relationships (Cleveland Clinic, 3,000 nursing/assisted living facilities). However, substantial dilution (12,000 preferred shares convertible to 80M common shares, 19.99% capped), clinical validation risk unproven, and future revenue highly contingent on definitive agreements post-closing.
Tradability signal
NO TRADE
No trade: price $0.13 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.16 ▲ 19.08% | at our read · unknown $0.13 | +10 min · unknown $0.13 ▼ 0.76% | +30 min · unknown $0.13 ▼ 0.76% | +1 hr · unknown $0.13 ▲ 1.53% | +4 hrs · unknown $0.15 ▲ 12.21% |
The stock had already moved -16.03% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.